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https://doi.org/10.1016/j.stemcr.2020.05.009SUMMARYRetinal ganglion cells (RGCs) serve as the connection between the eye and the brain, with this connection disrupted in glaucoma.
Numerous cellular mechanisms have been associated with glaucomatous neurodegeneration, and useful cellular models of glaucoma
allow for the precise analysis of degenerative phenotypes. Human pluripotent stem cells (hPSCs) serve as powerful tools for studying hu-
man disease, particularly cellular mechanisms underlying neurodegeneration. Thus, efforts focused upon hPSCs with an E50Kmutation
in the Optineurin (OPTN) gene, a leading cause of inherited forms of glaucoma. CRISPR/Cas9 gene editing introduced the OPTN(E50K)
mutation into existing lines of hPSCs, as well as generating isogenic controls from patient-derived lines. RGCs differentiated from OPT-
N(E50K) hPSCs exhibited numerous neurodegenerative deficits, including neurite retraction, autophagy dysfunction, apoptosis, and
increased excitability. These results demonstrate the utility of OPTN(E50K) RGCs as an in vitromodel of neurodegeneration, with the op-
portunity to develop novel therapeutic approaches for glaucoma.INTRODUCTION
Glaucoma is a devastating optic neuropathy which causes
the progressive degeneration of retinal ganglion cells
(RGCs), leading to irreversible loss of vision and eventual
blindness (Gupta and Yucel, 2007; Hartwick, 2001; Quig-
ley, 2011). Various animal models have been developed
that have led to a greater understanding of glaucomatous
neurodegeneration (Agostinone and Di Polo, 2015; Cueva
Vargas et al., 2015; Kalesnykas et al., 2012; Williams
et al., 2013), although these models often exhibit physio-
logical features that do not precisely reflect those present
within human patients. Furthermore, recent studies
demonstrating significant variability between rodent and
primate RGCs (Peng et al., 2019) suggest that there may
be important differences in how these cells respond to glau-
comatous injuries between species. As such, there is a
strong need to develop new approaches to complement
these glaucoma models to determine RGC pathogenesis
and mechanisms leading to their degeneration and death.
Human pluripotent stem cells (hPSCs) provide an attrac-
tive option as a model for studies of cellular development
and disease progression as they can be cultured indefinitely
and induced to differentiate into all cell types of the body
(Thomson et al., 1998), including RGCs (Fligor et al.,52 Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 j ª 2020 The Author(s
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et al., 2017; Tanaka et al., 2015; Teotia et al., 2017a; Vander-
Wall et al., 2019). When harboring genetic mutations asso-
ciated with disease states, the derivation of these cells from
patient-specific sources allows for the ability to study
mechanisms underlying diseases, such as glaucoma (Ina-
gaki et al., 2018; Minegishi et al., 2013; Ohlemacher
et al., 2016; Teotia et al., 2017b). In addition, gene-editing
approaches, including CRISPR/Cas9 technology allow for
the ability to create isogenic controls from these patient-
derived cells and also introduce disease-causing mutations
in unaffected cells, leading to the generation of new disease
models (Cong et al., 2013; Muffat et al., 2016; Poon et al.,
2017). Among the gene mutations associated with glau-
coma, those mutations in the Optineurin (OPTN) gene
are known to result in glaucomatous neurodegeneration
in the absence of increased intraocular pressure (Fingert,
2011; Minegishi et al., 2016; Sarfarazi et al., 2003). These
mutations directly affect RGCs, with the OPTN(E50K) mu-
tation previously shown to result in a particularly severe
degenerative phenotype (Chalasani et al., 2014; Inagaki
et al., 2018; Meng et al., 2012; Rezaie et al., 2002; Tseng
et al., 2015; Ying et al., 2015). As such, the generation of
hPSCs harboring the OPTN(E50K) mutation, along with
corresponding isogenic controls, allows for the in vitro).
ecommons.org/licenses/by-nc-nd/4.0/).
analysis of mechanisms underlying the degeneration of
RGCs in glaucoma.
Thus, the efforts of the current study were initially
focused upon the generation of hPSCs with the
OPTN(E50K) mutation as well as their corresponding
isogenic controls through the use of CRISPR/Cas9 gene ed-
iting. Upon initial differentiation of these cells into three-
dimensional retinal organoids and subsequent RGC purifi-
cation, OPTN(E50K) and isogenic control cells both
developed in a similar manner, yielding a comparable
number of RGCs. Conversely, at later stages of RGC matu-
ration, OPTN(E50K) RGCs demonstrated numerous
characteristics associated with glaucomatous neurodegen-
eration, including neurite retraction, autophagy dysfunc-
tion, and increased excitability. The results of this study
provide the most comprehensive analysis of glaucomatous
neurodegeneration to date using hPSC-based models,
including the demonstration of CRISPR/Cas9 gene editing
to provide essential disease models and corresponding
isogenic controls for glaucoma.RESULTS
CRISPR/Cas9-Edited OPTN(E50K) Disease Models and
Isogenic Controls
The ability to precisely edit genes in hPSCs through
CRISPR/Cas9 gene-editing technology allows for new in-
sights into disease modeling, including the generation of
isogenic controls (Cong et al., 2013; Muffat et al., 2016;
Poon et al., 2017). When properly applied, CRISPR/Cas9
gene editing allows for the enhanced ability to analyze dis-
ease phenotypes due to relevant mutations by minimizing
genetic variability between cell lines. As such, CRISPR/Cas9
gene editing was utilized in the current study to examine
the E50K mutation in the OPTN protein, a known genetic
determinant for glaucoma.
To introduce the OPTN(E50K) mutation in hPSCs (Fig-
ure 1), the homology-directed repair (HDR) template was
designed to include the mutant nucleotide c.458G > A
that altered the 50th amino acid from glutamic acid (E)
to lysine (K), with an additional two silent mutations
(c.454G > C and c.460G > A). The first silent mutation
altered an Hpy188III restriction site, which was used for
PCR screening of prospective gene-edited clones. The sec-
ond silent mutation was introduced to prevent Cas9 from
cutting the donor template by modifying the PAM site. A
plasmid containing the OPTN(E50K) HDR template as
well as the guide RNA was co-transfected with pCas9-GFP,
with the GFP signal used to sort for presumptively edited
cells (Figures 1A–1C). Clonal populations were screened
by PCR amplification of the edited region and enzymatic
digestion with Hpy188III, with prospectively edited clonesfurther sequenced to ensure proper editing of the target
gene (Figure 1D). Likewise, patient-specific hiPSCs
harboring the OPTN(E50K) mutation utilized a similar
strategy to correct the OPTN(E50K) mutation (Figure 1E).
Following CRISPR/Cas9 gene editing, the karyotypes of
each cell line were analyzed to reveal normal karyotypes
(Figure S1). The results of these experiments demonstrated
the successful establishment of hPSC lines harboring the
OPTN(E50K) mutation along with their corresponding
isogenic controls.
OPTN(E50K) Glaucomatous RGCs Demonstrate
Morphological Deficits and Gene Downregulation
after Prolonged Culture
The degeneration of RGCs in glaucoma severely affects the
visual pathway, leading to blindness (Fingert, 2011; Gupta
and Yucel, 2007; Hartwick, 2001; Quigley, 2011). This
degeneration is commonly associated with advanced age,
as the initial development of the retina is unaffected
by the disease state. As such, the early differentiation of
OPTN(E50K) and isogenic control hPSCs yielded similar
formation of optic vesicle-like and optic cup retinal organo-
ids and a comparable number of RGCs (Figure 2).
Previous studies in animal models of RGC damage have
demonstrated significant neurite retraction and dendritic
remodeling in response to RGC injury and disease (Agosti-
none and Di Polo, 2015; Agostinone et al., 2018; Kalesny-
kas et al., 2012; Williams et al., 2013). To examine if this
phenomenon could be recapitulated in an hPSC model,
OPTN(E50K) and isogenic control RGCs were examined
in a temporal fashion for morphological characteristics
associated with neuronal maturation (Figure 3). Represen-
tative inverted fluorescent images (Figures 3A–3H) and
neurite tracings (Figures 3I–3P) of OPTN(E50K) and
isogenic control RGCs revealed high degrees of similarity
in neuronal maturation from 1 to 3 weeks after purifica-
tion. By 4 weeks of maturation, however, OPTN(E50K)
RGCs displayed deficits in neurite complexity, cell
body size, and neurite length (Figures 3Q–3S), as well as
in the expression of various synaptic proteins (Figure S2).
These results suggested that OPTN(E50K) and isogenic
control RGCs exhibited similar morphological profiles
during the early stages but, following maturation,
OPTN(E50K) RGCs significantly reduced their morpholog-
ical complexity, similar to what has been previously
observed for glaucomatous RGCs in vivo.
Previous studies in animal models of RGC injury have
also demonstrated the downregulation of RGC-associ-
ated proteins before the degeneration of these cells
(Soto et al., 2008; Weishaupt et al., 2005). As such, efforts
were made to determine if RGC-associated proteins were
similarly downregulated in OPTN(E50K) RGCs (Figure 4).
As a percentage of the total cell population, theStem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 53
Figure 1. CRISPR/Cas9 Gene Editing for the Generation of OPTN(E50K) hPSCs and Corresponding Isogenic Controls
(A) Schematic displaying the workflow for the CRISPR/Cas9 gene editing of hPSCs.
(B) A subset of GFP-positive cells was observed in hPSCs expressing Nanog and Tra1-81 after electroporation.
(C) Flow cytometry indicated the gating of GFP-positive cells 48 h after electroporation.
(D and E) CRISPR/Cas9-edited cells were screened for the insertion of the OPTN(E50K) mutation in wild-type hPSCs (D) and correction of
the mutation in patient-derived hPSCs (E) by restriction digestion with Hpy188III and Sanger sequencing. The 50th codon of the OPTN
gene is highlighted in yellow. The red arrows highlight the insertion or correction of the OPTN(E50K) missense mutation site in Sanger
sequencing. Scale bar, 50 mm (B).expression of the RGC transcription factors BRN3B and
ISL1 were significantly decreased in OPTN(E50K) RGCs
compared with isogenic controls (Figures 4A and 4B).
To determine if this decrease was a result of gene down-54 Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020regulation or loss of cells, the expression of each was
compared with the expression of the RGC-associated
cytoskeletal marker MAP2. No significant differences
were observed in the percentage of MAP2-positive cells
Figure 2. The OPTN(E50K) Mutation Does Not Affect Early Stages of Retinal Differentiation
(A–D) Immunocytochemistry analyzed the expression of PAX6 (A and B) and CHX10 (C and D) at 30 days of differentiation, revealing no
significant differences between OPTN(E50K) and isogenic control retinal organoids.
(E and F) Similarly, both conditions demonstrated similar expression patterns for BRN3B:tdTomato within inner layers and Recoverin
within outer layers of retinal organoids after 60 days of differentiation.
(G–M) RGCs dissociated from OPTN(E50K) (H, J, and L) and isogenic control (G, I, and K) retinal organoids demonstrated no significant
differences in the expression of BRN3B:tdTomato, RBPMS, and SNCG (M). Error bars represent SEM (n = 5 separate differentiation
experiments each using OPTN(E50K) hiPSCs, OPTN- corrected hiPSCs, and H7 and H7(E50K) hPSCs). Scale bars, 100 mm (A–F) and 50 mm
(G–L).between OPTN(E50K) and isogenic control RGCs; how-
ever, the colocalization of either BRN3B or ISL1 with
MAP2 was significantly reduced in the OPTN(E50K) con-
dition. Conversely, retinal progenitor cells and photore-
ceptors were unaffected by the OPTN(E50K) mutation,
with a specific loss of BRN3-expressing RGCs (Figures4C and 4D). Minimal colocalization was identified be-
tween MAP2 and retinal progenitors or photoreceptors
marked by CHX10, recoverin, and OTX2, suggesting a
high specificity of MAP2 to RGCs (Figures 4E–4G). These
results suggested an early downregulation of RGC-associ-
ated transcription factors in response to the OPTN(E50K)Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 55
(legend on next page)
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mutation, indicative of an increased susceptibility to
subsequent glaucomatous neurodegeneration.
Functional Consequences of the OPTN(E50K)
Glaucomatous Mutation
Previous studies have demonstrated changes in RGC excit-
ability associated with the glaucomatous disease state
(Cueva Vargas et al., 2015) and, as such, patch-clamp ana-
lyses determined if functional changes were present in
OPTN(E50K) RGCs (Figure 5). Within 4 weeks of RGC
maturation, both OPTN(E50K) and isogenic control RGCs
demonstrated functional properties, including ionic
currents as well as spontaneous firing of action potentials
(Figures 5A and 5B). No significant changes were detected
in the resting membrane potential (Figure 5C), although
OPTN(E50K) RGCs displayed a significantly lower cell
capacitance, higher input resistance, as well as lower action
potential current threshold (Figures 5D–5F), suggesting
possible changes to excitable properties. To test this, cur-
rent-clamp recordings demonstrated that OPTN(E50K)
RGCs fired significantly more action potentials (Figures
5G and 5H). These results demonstrated an increased
excitability of OPTN(E50K) RGCs, suggesting that excito-
toxicity may play a key role in the early stages of RGC
degeneration in glaucoma.
RNA Sequencing Demonstrated Differential Gene
Expression in OPTN(E50K) RGCs
To elucidate gene expression differences and the specific
cellular pathways affected by the OPTN(E50K) mutation,
RNA sequencing was conducted on RGCs purified
from OPTN(E50K) and isogenic control retinal organoids
(Figure 6). Initial analysis demonstrated 75 downregulated
genes and 117 upregulated genes associated with
OPTN(E50K) RGCs when compared with isogenic control
RGCs (Figure 6B). Of the downregulated genes, a number
of genes were associated with the clearance of aggregated
proteins, protein trafficking, and neurite outgrowth.
Pathway analyses revealed changes in gene expression
associated with a variety of neurodegenerative diseases,
including amyotrophic lateral sclerosis (ALS) and Alz-
heimer disease, as well as the downregulation of pathways
related to autophagy and neurite outgrowth (Figure 6C).
Thus, as RNA sequencing results demonstrated differentialFigure 3. OPTN(E50K) RGCs Demonstrate Neurite Deficits at Late
(A–P) Inverted fluorescent images (A–H) and representative neurite
4 weeks after purification from retinal organoids. Similar neurite com
OPTN(E50K) RGCs became apparent at 4 weeks.
(Q) A significantly lower number of ordered neurites and branch poin
(R and S) OPTN(E50K) RGCs also demonstrated significantly shorter ne
bars represent SEM (n = 4 separate differentiation experiments eac
H7(E50K) hPSCs) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.00gene expression and pathways suggesting autophagy
dysfunction, opportunities to examine deficits in auto-
phagy associated with this mutation were further pursued.
OPTN(E50K) RGCs Exhibit Autophagy Disruption and
Increased Susceptibility to Apoptosis
TheOPTN protein plays an important role as an autophagy
receptor (Minegishi et al., 2016; Sirohi and Swarup, 2016;
Slowicka et al., 2016; Ying and Yue, 2016), with mutations
to theOPTN protein, such as the E50Kmutation disrupting
the autophagy pathway leading to the damage and degen-
eration of RGCs (Chalasani et al., 2014; Inagaki et al., 2018;
Meng et al., 2012; Minegishi et al., 2013; Ying et al., 2015).
As such, to elucidate possible disruptions to the autophagy
pathway, retinal organoids were examined for the expres-
sion of LC3, particularly the accumulation of this protein
as a hallmark of autophagy dysfunction (Figure 7).
Compared with isogenic controls, OPTN(E50K) organoids
exhibited profound LC3 accumulation exclusively within
inner layers where RGCs reside, indicating a differential ef-
fect upon these cells (Figures 7A–7F). To test the possibility
of rescuing this phenotype, the autophagy pathway was
enhanced through treatment with rapamycin, leading
to a significant reduction of LC3 accumulation within
OPTN(E50K) organoids (Figures 7G–7I). As such, disrup-
tions to the autophagy pathway likely contribute to the
degeneration of OPTN(E50K) RGCs, with rescue of this
phenotype by rapamycin suggesting modulation of auto-
phagy may rescue degenerative phenotypes.
To determine if autophagy disruption was correlated
with a decrease in RGC viability, retinal organoids were
similarly examined for apoptosis, with OPTN(E50K) orga-
noids exhibiting significantly increased levels of activated
caspase-3 found largelywithin inner layers of these organo-
ids (Figures 7M–7P). In addition, OPTN(E50K) organoids
contained significantly fewer BRN3-expressing RGCs,
while the number of photoreceptors quantified by expres-
sion ofOTX2 revealedno significant differences (Figure S3).
Retinal organoids were then treated with rapamycin to
determine if an association existed between apoptosis
and autophagy. When treated with rapamycin,
OPTN(E50K) organoids displayed decreased levels of active
caspase-3 (Figures 7Q–7S), suggesting an important link
between autophagy dysfunction and apoptosis.r Stages of Maturation
tracings (I–P) of isogenic control and OPTN(E50K) RGCs from 1 to
plexity was initially observed, but significant neurite retraction in
ts were observed in OPTN(E50K) RGCs after 4 weeks.
urites (R) and smaller soma sizes (S) by 4 weeks of maturation. Error
h using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and
01). Scale bars, 25 mm (A–H) and 100 mm (I–P).
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Figure 4. OPTN(E50K) RGCs Downregulate RGC-Associated Transcription Factors
(A and B) The expression of RGC-associated transcription factors BRN3B:tdTomato (A) and ISL1 (B) was correlated with the RGC-associated
cytoskeletal marker MAP2, with this correlation decreased in the OPTN(E50K) cell lines.
(C and D) Conversely, minimal correlation was observed between MAP2 and markers of retinal progenitor cells (C, CHX10) and photore-
ceptors (D, OTX2).
(E) A significant decrease was observed in the expression of BRN3B and ISL1 in OPTN(E50K) RGCs relative to the total number of DAPI-
positive cells, with no differences observed in MAP2-expressing cells nor CHX10-expressing retinal progenitor cells or Recoverin/OTX2-
expressing photoreceptors.
(F) A significant decrease in co-expression for BRN3 or ISL1 RGCs was observed, with no changes observed for other cell types.
(G) Lastly, as either a percentage of the total cell population or among the MAP2-expressing cells, changes in cell numbers were only
observed among RGCs as identified by BRN3 expression. Error bars represent SEM (n = 3 separate differentiation experiments each using
OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and H7(E50K) hPSCs) (**p < 0.01, ***p < 0.001). Scale bars, 25 mm (A–D).DISCUSSION
hPSCs have been used as a reliablemodel system for study-
ing both the development of many retinal cell types58 Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020(Lamba et al., 2006; Lu and Barnstable, 2019; Meyer
et al., 2011; Sridhar et al., 2020; Zhong et al., 2014) as
well as diseases which result in the degeneration of these
cells (Ohlemacher et al., 2016; Sridhar et al., 2018; Teotia
Figure 5. OPTN(E50K) RGCs Display Increased Excitability
(A and B) OPTN(E50K) RGCs and isogenic controls displayed similar abilities to conduct inward sodium and outward potassium currents (A)
as well as the ability to fire spontaneous action potentials (B).
(C) No significant differences were identified in the resting membrane potential between OPTN(E50K) RGCs and isogenic controls.
(D–F) OPTN(E50K) RGCs demonstrated significantly lower cell capacitance (D), higher input resistance (E), and a lower action potential
current threshold (F) compared with isogenic controls.
(G and H) Representative traces of evoked action potentials (G) following current injections revealed the firing of significantly more action
potentials (H) in OPTN(E50K) RGCs compared with isogenic controls. Error bars represent SEM (n = 2 separate differentiation experiments
using H7, n = 28 technical replicates and H7(E50K) hPSCs, n = 46 technical replicates) (*p < 0.05, **p < 0.01, ***p < 0.001).et al., 2017b). The current understanding of glaucomatous
neurodegeneration has been established in part by the use
of animal models mimicking RGC degeneration and
injury (Agostinone et al., 2018; Kalesnykas et al., 2012;
Tseng et al., 2015; Williams et al., 2013). Although these
studies have been instrumental in discovering various
disease phenotypes, important differences exist between
rodent and primate retinas (Peng et al., 2019). As
such, the use of hPSCs provides a powerful and compli-
mentary model to study RGC development and disease
that helps to bridge the gap between rodent studies and
human glaucoma patients. Results of the current study
demonstrate the most in depth phenotypic and func-
tional characterization of RGCs grown from OPTN(E50K)
hPSCs, revealing numerous neurodegenerative pheno-types including autophagy deficits and neurite retraction,
allowing for a greater understanding of mechanisms
leading to the degeneration and death of RGCs in
glaucoma.
CRISPR/Cas9 gene editing provides exciting opportu-
nities for the precise engineering of cells to generate new
experimental models (Cong et al., 2013; Muffat et al.,
2016; Poon et al., 2017). Of particular interest for this
study, CRISPR/Cas9 gene editing allowed for the insertion
of disease-causing mutations in hPSCs as well as the
correction of these mutations in patient-specific hPSCs,
minimizing effects due to variability between cell lines.
As previous studies have demonstrated variability in the
capacity of numerous hPSC lines to differentiate into
retinal cells (Capowski et al., 2019; Meyer et al., 2011),Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 59
Figure 6. RNA Sequencing Revealed Differential Gene Expression and Pathway Analysis in OPTN(E50K) RGCs
(A) A schematic demonstrates the workflow of RNA sequencing from OPTN(E50K) and isogenic control retinal organoids (n = 4 for isogenic
control and n = 4 for OPTN(E50K)).
(B) Differential gene expression analysis demonstrated 75 downregulated genes and 117 upregulated genes in OPTN(E50K) RGCs when
compared with isogenic control RGCs (p < 0.05).
(C) Pathway analysis revealed a variety of upregulated and downregulated pathways associated with glaucomatous neurodegeneration (p <
0.1). n = 5 separate differentiation experiments using H7 and H7(E50K) hPSCs.this variability complicates the definitive identification of
disease-related phenotypes apart from inherent differ-
ences between cell lines. The use of CRISPR/Cas9 gene ed-
iting in the current study allowed for the definitive identi-
fication of disease-related phenotypes directly linked to
the OPTN(E50K) mutation. As such, the results of this
study provide the foundation for utilizing CRISPR/Cas9
gene editing of hPSCs for the study of other genetically in-
herited forms of glaucoma as well as other neurodegener-
ative diseases of the retina to discover mechanisms of
degeneration.60 Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020The age-related loss of RGCs in glaucoma is characteristic
of the loss of neurons found in many neurodegenerative
diseases (Chu, 2019; Edens et al., 2016; Gupta and Yucel,
2007; Hartwick, 2001; Hirt et al., 2018; Lai et al., 2017;
Mancino et al., 2018; Moloudizargari et al., 2017; Nixon,
2013; Wostyn et al., 2019). In this context, RGCs differen-
tiate normally during early retinogenesis, with degenera-
tion associated with age and disease progression. As such,
it is crucial for model systems of glaucoma to demonstrate
this type of disease progression in vitro. Results of the cur-
rent study suggested thatOPTN(E50K) and isogenic control
Figure 7. OPTN(E50K) Retinal Organoids Demonstrate Autophagy Dysfunction through LC3 Accumulation
(A–I) Retinal organoids from isogenic control, OPTN(E50K), and OPTN(E50K) plus rapamycin conditions displayed proper organization
with BRN3B:tdTomato expression confined within inner layers. Compared with isogenic controls (A–C), LC3 accumulations were found
specifically within the inner layers of OPTN(E50K) organoids (D–F), with accumulation rescued by rapamycin treatment (G–I). Arrowheads
in (E) indicate LC3 accumulations.
(J–L) Significantly more LC3 puncta (J) were observed in OPTN(E50K) organoids compared with isogenic controls or rapamycin-treated
organoids, with accumulations larger in both puncta size (K) and total area (L).
(M–S) OPTN(E50K) retinal organoids (O and P) also displayed significantly higher levels of active caspase-3 within inner layers compared
with outer layers as well as corresponding isogenic controls (M and N), with increased active caspase-3 rescued by rapamycin (Q and R).
Error bars represent SEM (n = 3 separate differentiation experiments each using OPTN(E50K) hiPSCs, OPTN-corrected hiPSCs, and H7 and
H7(E50K) hPSCs) (*p < 0.05, ****p < 0.0001). Images in (C), (F), and (I) are higher magnification representations of samples analyzed in
(B), (E), and (H). Scale bars, 50 mm.hPSCs both differentiated into early optic cup-like retinal
organoids that displayed a lamination of retinal layers.
When organoids were dissociated and resultant cells grown
in two-dimensional cultures, no significant differences
were observed in the initial expression of RGC-associated
markers as well as the morphological features of neuronal
maturation. Disease phenotypes including neurite retrac-
tion, autophagy dysfunction, and apoptosis were only
identified in OPTN(E50K) cells after prolonged culture,
with this progression somewhat recapitulating theage-related phenotypes observed in glaucomatous
neurodegeneration.
The downregulation of RGC-associated transcription fac-
tors has been previously established in experimental glau-
coma as well as RGC injury models, which provides an
early indicator of degeneration in the retina (Soto et al.,
2008; Weishaupt et al., 2005). Results of the current study
demonstrated the downregulation of the RGC-associated
transcription factors BRN3 and ISL1 in OPTN(E50K)
RGCs compared with isogenic controls. Importantly, thisStem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 61
downregulation of BRN3 and ISL1 was only identified after
prolonged culture, with quantification at earlier time
points indicating no significant differences between OPT-
N(E50K) RGCs and isogenic controls. In future experi-
ments using fluorescent reporters to identify RGCs in
hPSC disease models, it will be necessary to account for
the downregulation of these reporters to identify those
RGCs at advanced stages of the disease state.
The OPTN protein performs a variety of functions
within the cell, including its role as an autophagy receptor
(Minegishi et al., 2016; Sirohi and Swarup, 2016; Slowicka
et al., 2016; Ying et al., 2015; Ying and Yue, 2016). As such,
OPTN interacts with a variety of essential autophagy pro-
teins, with the E50K mutation in this protein leading to a
disruption in this pathway. Autophagy pathway disrup-
tion has also been linked to neurodegeneration in a num-
ber of other diseases, including ALS, Alzheimer, and Par-
kinson diseases, with the possibility of deficits in this
pathway conserved as a mechanism leading to the degen-
eration of neurons (Chu, 2019; Edens et al., 2016; Hirt
et al., 2018; Lai et al., 2017; Mancino et al., 2018; Molou-
dizargari et al., 2017; Nixon, 2013;Wostyn et al., 2019). In
this study, results demonstrated profound accumulation
of LC3 and significantly higher levels of apoptosis within
inner layers compared with both the outer layers of these
same organoids as well as the presumptive RGC layers of
isogenic controls. When treated with rapamycin, an acti-
vator of the autophagy pathway, these phenotypes were
reduced back to levels comparable with isogenic controls,
reflecting an important balance between the autophagy
and apoptotic pathways linked to the OPTN(E50K)
mutation.
The overstimulation of cells through excitotoxic mecha-
nisms has been implicated in a variety of neurodegenera-
tive diseases including glaucoma (Cueva Vargas et al.,
2015; Dzialo et al., 2013; Hynd et al., 2004). Results of
this study demonstrated that OPTN(E50K) RGCs exhibited
a significantly lower action potential current threshold
than isogenic controls, leading to the firing of significantly
more action potentials, with these results suggesting that
the increased excitability of OPTN(E50K) RGCs may serve
as a key contributor to their degeneration. Importantly,
both OPTN(E50K) and isogenic control RGCs were identi-
fied for patch-clamp recordings based upon their expres-
sion of BRN3B:tdTomato fluorescence. Given that the
results of this study also documented the downregulation
of BRN3B:tdTomato in more advanced stages of
OPTN(E50K) RGC maturation, the possibility exists that
the phenotypes observed may represent an earlier stage
of the degenerative process, with these phenotypes more
severe in those RGCs which are more advanced in their
degeneration and have downregulated the tdTomato
reporter.62 Stem Cell Reports j Vol. 15 j 52–66 j July 14, 2020Although glaucoma is often overlooked as a neurodegen-
erative disease, it bears many similarities to other CNS dis-
eases, such as Parkinson, ALS, and Alzheimer, which ulti-
mately result in the degeneration of neurons in either the
brain or spinal cord (Chu, 2019; Edens et al., 2016; Gupta
and Yucel, 2007; Hirt et al., 2018; Lai et al., 2017; Mancino
et al., 2018; Moloudizargari et al., 2017; Nixon, 2013; Wos-
tyn et al., 2019). Similar to previous studies of RGC damage
as well as cortical neurons in Alzheimer disease (Agosti-
none and Di Polo, 2015; Agostinone et al., 2018; Kalesny-
kas et al., 2012; Williams et al., 2013), results of this study
identified numerous deficits including the downregulation
of important RGC transcription factors, neurite retraction,
autophagy disruption, and apoptosis, as well as heightened
excitability of RGCs, all of which have previously been
associated with other neurodegenerative diseases. As
such, the results and assays conducted in this study are
not only relevant to the study of glaucoma, but also to
many other diseases of the CNS, with the possibility to
work collectively on targeted therapeutics at these distinc-
tive pathways.
Overall, the results of this study demonstrate a detailed
characterization of the OPTN(E50K) mutation and how it
affects the degeneration of RGCs. More so, this study
extensively utilized CRISPR/Cas9 gene-editing technology
for the generation of diseasemodels as well as isogenic con-
trols for studies of glaucoma, with an important emphasis
on the discrimination between mutation-causing pheno-
types and cell line variability. In future studies using
hPSC-based models of glaucomatous neurodegeneration,
the identification of other unique neurodegenerative phe-
notypes and specific pathways leading to those phenotypes
should be considered to better target therapeutic strategies.EXPERIMENTAL PROCEDURES
CRISPR/Cas9 Gene Editing
TheOPTN(E50K)mutationwas inserted into H7BRN3B:tdTomato-
Thy1.2-hESCs (Sluch et al., 2017; Thomson et al., 1998) and an
hiPSC line harboring the OPTN(E50K) mutation (Ohlemacher
et al., 2016) was corrected (see Supplemental Experimental Proced-
ures for details). Electroporation was performed using the Neon
transfection system and, subsequently, cells were plated onto Ma-
trigel-coated plates in mTeSR1 medium with CloneR supplement
(STEMCELLTechnologies). Forty-eight hours after electroporation,
GFP-positive cells were isolated by FACS to enrich for edited cells.
After initial growth, clonal populations were isolated and
expanded. To screen for the insertion/correction, genomic DNA
from individual clones was extracted, and the portion of the
OPTN gene containing the 50th codon was amplified by PCR.
This PCR product was then enzymatically digested by Hpy188III
and run on a 1% gel. Properly edited clones were further confirmed
by Sanger sequencing, and chromosomal abnormalities were
analyzed by G-banded karyotyping.
Maintenance of hPSCs
hPSCs were cultured from OPTN(E50K) disease lines and corre-
sponding isogenic controls based on previously described proto-
cols (Fligor et al., 2020; Meyer et al., 2011; Ohlemacher et al.,
2015). In brief, hPSC colonies were maintained on a Matrigel-
coated six-well plate in mTeSR1 medium, with daily medium
changes. hPSCs were passaged every 4–5 days based upon their
confluency. Before passaging, hPSCs were marked for areas of
spontaneous differentiation and those areas were mechanically
removed. At 70% confluency, hPSCs were enzymatically passaged
with dispase (2 mg/mL) for approximately 15min and split at a ra-
tio of 1:6 onto a new six-well plate freshly coated with Matrigel.
Differentiation of RGCs
hPSCs were differentiated into retinal organoids and RGCs using
an established protocol with minor modifications (Fligor et al.,
2020; Ohlemacher et al., 2015). In brief, enzymatically passaged
hPSC colonies were grown in suspension to produce embryoid
bodies (EBs). Within the first 3 days of differentiation, EBs were
slowly transitioned from mTesR1 medium into neural induction
medium. On day 6 of differentiation, BMP4 (50 ng/mL) was
added to the flask (Capowski et al., 2019). The same medium
was used at day 8 to induce adherence of EBs to a plate supple-
mented with 10% fetal bovine serum. Half of the medium was
changed at day 9 and 12 to slowly reduce the concentration of
BMP4. At day 15, early optic vesicle colonies were mechanically
lifted and transferred into retinal differentiation medium, with
a medium change every 2 to 3 days. At 30 days of differentiation,
early retinal organoid cultures were supplemented with Gluta-
MAX and 2% fetal bovine serum to aid in retinal organization.
By day 45, retinal organoids were either enzymatically dissociated
in Accutase for RGC purification, or preserved as floating organo-
ids for cryosectioning. For some experiments, retinal organoids
were treated with rapamycin (2 mM) for 24 h and then fixed for
immunocytochemistry.
To purify RGCs, retinal organoidswere enzymatically dissociated
into single cells using Accutase for 20 min at 37C. Single-cell sus-
pensions were then enriched for RGCs with the Thy1.2 surface re-
ceptorusing theMACScell separationkit (Sluchet al., 2017). A total
of 10,000 RGCs were plated on poly-D-ornithine and laminin-
coated12-mmcoverslipsandmaintained forup to4weeks inBrain-
Phys medium (Bardy et al., 2015; VanderWall et al., 2019). To
analyze neurite complexity, RGCswere transfected withGFP using
lipofectamine 2 days before fixation to aid in identification of indi-
vidual RGC neurites along with BRN3:tdTomato expression.
Immunocytochemistry
Samples were fixed with 4% paraformaldehyde in phosphate-buff-
ered solution (PBS) for 30 min followed by 3 PBS washes. Retinal
organoids were then prepared for cryosectioning through an incu-
bation in 20% sucrose solution for 1 h at room temperature, fol-
lowed by an incubation in 30% sucrose solution overnight at
4C. The following day, retinal organoids were transferred into
OCT cryostat molds and snap-frozen on dry ice. Sections (12 mm)
were cut and used for immunocytochemical analyses.
Following fixation or sectioning, samples were permeabilized in
0.2% Triton X-100 for 10 min at room temperature. Samples werethenwashedwith PBS and blockedwith 10%donkey serum for 1 h
at room temperature. Primary antibodies (Table S1) were diluted in
0.1% Triton X-100 and 5% donkey serum and applied overnight at
4C. The next day, the primary antibodywas removed and samples
were washed three times with PBS and blocked with 10% donkey
serum for 10 min at room temperature. Secondary antibodies
were diluted at 1:1,000 ratio in 0.1% Triton X-100 and 5% donkey
serum and applied to samples for 1 h at room temperature. The sec-
ondary antibodies were then removed and samples were washed
three times with PBS before mounting onto slides for imaging.
Immunofluorescent images were obtained using a Leica DM5500
fluorescence microscope.
Data Quantification
Isogenic control and OPTN(E50K) RGCs were collected at 1, 2, 3,
and 4 weeks after purification and analyzed based on neurite
complexity, neurite length, and soma size. Several immunofluores-
cent images were taken of RGCs co-expressing tdTomato and GFP,
and soma area and neurite complexity were quantified using Im-
ageJ and Photoshop, with the NeuronJ plugin used to quantify
the length of RGC neurites.
Organoids from isogenic control, OPTN(E50K), andOPTN(E50K)
plus rapamycin sources were collected at 2.5 months of differenti-
ation and quantified for expression of BRN3, OTX2, and caspase-3
using the cell counter plugin in ImageJ. LC3 puncta number, size,
and area were quantified using the ImageJ particle analyzer. Orga-
noid areas were also quantified using ImageJ plugins. For caspase-3
quantification, organoid sections were imaged and the inner and
outer layers were traced based on the expression of BRN3:tdTo-
mato in Photoshop. The areas of inner and outer layers were deter-
mined using ImageJ and the cell counter plugin was used to quan-
tify caspase-3 fragments in each layer.
Statistical Analyses
Statistical significance for neurite complexity, soma size, neurite
length, and electrophysiological recordings was performed using
two-tailed Student’s t test and significance based on a p value
of < 0.05. Significance for BRN3 and ISL1 quantifications were
achieved by a Student’s t test based on a p value of < 0.05. For
BRN3, OTX2, caspase-3, and LC3 accumulations, a one-way
ANOVA followed by a Tukey’s post hoc analysis was used to deter-
mine significance based on a p value < 0.05.
Electrophysiology
Whole-cell patch-clamp recordings were performed at room tem-
perature (~22C) using a HEKA EPC-10 amplifier as described pre-
viously (VanderWall et al., 2019), with detail provided in Supple-
mental Experimental Procedures. RGCs were identified by
tdTomato fluorescence. To enhance comparisons between cells
during action potential activity recording, current was injected
to bias the cell membrane potential to 70 mV. Current threshold
for action potential generation was obtained by a series of 1-ms
stimuli of increasing intensity, with the maximum number of ac-
tion potentials elicited measured during a series of 500-ms stimuli
of increasing intensity. Voltage-clamp recordings were obtained
from each cell at the end of the series of current-clamp protocols.
The peak amplitudes of sodium and potassium currents wereStem Cell Reports j Vol. 15 j 52–66 j July 14, 2020 63
measured using a standard I-V protocol with a holding potential at
80 mV. The current density was calculated by normalizing
current amplitude to the capacitance of each cell.
RNA Sequencing Preparation and Analysis
RGCs were immunopurified from organoids after 45 days of
differentiation and grown in adherent cultures for 10 days in
BrainPhys medium. RNA was collected using the PicoPure RNA
isolation kit. Total RNA was evaluated for its quantity and
quality using an Agilent Bioanalyzer 2100. Approximately 30
million reads per library were generated. The sequencing data
were next assessed using FastQC (Babraham Bioinfomatics,
Cambridge, UK) and then mapped to the human genome
(GRCH38) using STAR RNA sequencing aligner (Dobin et al.,
2013). Differentially expressed genes were tested by using
DESeq2 with a false discovery rate < 0.05 as the significant
cutoff (Love et al., 2014). Pathway enrichment analysis were
conducted by hypergeometric test against human gene ontology
and MsigDB v.6 canonical pathways, with p < 0.01 as the signif-
icant cutoff (Subramanian et al., 2005). The RNA sequencing ex-
periments reported in this paper have been deposited in the
Gene Expression Omnibus database, www.ncbi.nih.gov/geo
(accession no. GSE145069).
DATA AND CODE AVAILABILITY
All sequencing data have been deposited to GEO under accession
number GEO: GSE145069.
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